Gastroenterology · AntiemeticLabel Changeregulatorynear-term

Domperidone Updated with New Contraindication for Phaeochromocytoma Patients

Importance8/ 10

ActionInvestigate

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/22/2026, 6:02:04 AM

Assessment confidence: 75% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The new contraindication for domperidone in patients with phaeochromocytoma significantly alters its safety profile, which may lead to reduced prescribing and impact market share. Pharma strategy teams must assess the implications for their portfolios and develop strategies to address potential declines in usage. Regulatory context from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) supports the near-term read. Assessment grounded in 3 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this contraindication on domperidone's market positioning and consider strategies to mitigate potential declines in usage. The strongest clinical anchor is A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov), sponsor/company relevance (lilly). In cardiology, 2 regulatory and 0 competitive items passed relevance filtering for Domperidone.

Competitive Pressure

The most relevant competitive pressure comes from This label change may impact the prescribing practices of domperidone, potentially reducing its use in patients with this condition and affecting market share..

Regulatory Outlook

Regulatory risk is concentrated around Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension (MHRA). Sub-indication match (cardiology); Entity match (domperidone). Relevant agencies in corpus: MHRA, FDA. This label change necessitates immediate attention to ensure compliance with updated safety standards and to manage the implications for product marketing and physician education.

Key Risks

Elevated high regulatory exposure for Domperidone could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) could weigh on Domperidone through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Domperidone through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

The contraindication could lead to a substantial decrease in prescriptions, directly affecting revenue and market positioning for domperidone products.
Upside for Domperidone may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Upside for Domperidone may improve if A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this contraindication on domperidone's market positioning and consider strategies to mitigate potential declines in usage.

What Would Change This Assessment

This becomes more urgent if Monitor prescribing trends and any subsequent safety reports related to domperidone in the context of this new contraindication.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
MHRAhigh relevance
Sub-indication match (cardiology); Entity match (domperidone)
FDA document
View source
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAlow relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Updated warnings for botulinum toxin products following rare cases of botulism
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Point-of-Care Echocardiography in Patients With Known or Suspected Aortic Stenosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Baxter Faces Early Alert Over Intravascular Administration Set Air Bubble Issue
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Accepts Supplemental NDA for Linzess by AbbVie
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and safety of ultrasound ablation for uterine fibroids in patients with abdominal surgical scars on the acoustic pathway.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Domperidone

Commercial impact

high

The contraindication could lead to a substantial decrease in prescriptions, directly affecting revenue and market positioning for domperidone products.

Regulatory impact

high

This label change necessitates immediate attention to ensure compliance with updated safety standards and to manage the implications for product marketing and physician education.

What to watch

Monitor prescribing trends and any subsequent safety reports related to domperidone in the context of this new contraindication.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.